Journalists

Media & Press relations

Our latest press releases

July 30, 2024

bioMérieux Receives 10 Clinical Laboratory Awards for Excellence in Customer Satisfaction, System Performance and Service

bioMérieux, a world leader in in vitro diagnostics, received 10 IMV ServiceTrak™ Clinical Laboratory Awards today in the categories of microbial identification and susceptibility testing, Blood Culture, Immunoassay, and Molecular Diagnostics. The awards symbolize bioMérieux’s high-quality comprehensive customer service and system performance.

Discover more

Swipe for more

June 26, 2024

bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini

bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance and CLIA-waiver (Clinical Laboratory Improvement Amendments).

Read more
June 21, 2024

bioMérieux receives US FDA 510(k) clearance for its AST System VITEK® REVEAL™

bioMérieux, a world leader in in vitro diagnostics, today announces that its VITEK® REVEAL™ AST System, reporting results directly from positive blood cultures, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.

Read more
May 28, 2024

bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury

bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury (mTBI), including concussion.

Read more